Biopharma · FDA Approvals · Stock

OBX Obsidian Therapeutics

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to lev…

Assets on file: amsoki-cel

Start live analysis of OBX Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for OBX, including recently decided ones.

November 2026

Nov 2026

Nov 7, 2026

in 7 days

OBOBXObsidian Therapeutics, Inc.

Obsidian to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data at SITC 2026

Conference presentationCompany press release

June 2029

Jun 2029

Jun 30, 2029

in 973 days

OBOBXObsidian Therapeutics, Inc.

amsoki-cel: Phase 1/Phase 2 trial NCT06060613 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Recent first-hand events

Every first-hand event for OBX, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 5, 2026

03:22 PM

OBOBXObsidian Therapeutics, Inc.

amsoki-cel · NCT06060613 registry update

enrollment: 208 → 254

Trial registry changeClinicalTrials.gov

Oct 2, 2026

01:05 PM

OBOBXObsidian Therapeutics, Inc.

Obsidian to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data at SITC 2026

Obsidian will present pooled safety data from the FIH and Agni-01 studies plus updated efficacy from 15 patients treated at the RP2D of amsoki-cel in ICI-resistant advanced melanoma, plus a trial-in-progress poster on the Phase 2 registration-enabling cohort, at the SITC 2026 Annual Meeting on November 7, 2026. This is an update to previously disclosed Phase 1/2 data for the engineered TIL therapy.

Conference presentationCompany press release